🔗 Visit the ClinicalTrials.gov page for NCT01320085
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. | Lancet Oncol | 2013 | 4.26 |
| 2 | Ras in cancer and developmental diseases. | Genes Cancer | 2011 | 2.68 |
| 3 | Melanoma: new insights and new therapies. | J Invest Dermatol | 2012 | 1.54 |
| 4 | Beyond BRAF: where next for melanoma therapy? | Br J Cancer | 2014 | 1.26 |
| 5 | Targeting the RAS oncogene. | Expert Opin Ther Targets | 2013 | 1.02 |
| 6 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. | Front Oncol | 2013 | 0.89 |
| 7 | Transcriptional regulation of autophagy in RAS-driven cancers. | J Clin Invest | 2015 | 0.76 |
| 8 | Therapeutic Approaches to RAS Mutation. | Cancer J | 2016 | 0.76 |
| 9 | Targeting mutant NRAS signaling pathways in melanoma. | Pharmacol Res | 2016 | 0.75 |